Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2018-05-20 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 133.6KB
Regulatory Filings
2018-05-20 English
Admedus enters distribution agreement for Spain 2 pages 80.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Admedus Limited about securing a distribution agreement with Cardiva. It is a corporate news release about a business partnership and distribution deal, not a financial report, earnings release, or regulatory filing. The document is short (3846 characters) and contains no financial data, no mention of fiscal periods, no voting results, no management changes, and no legal proceedings. It is clearly a capital/financing update related to business development and distribution expansion. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-05-16 English
Appendix 3B - Placement of shares 14 pages 920.8KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the issuance of new shares by Admedus Limited, including an Appendix 3B form which is a standard Australian Securities Exchange (ASX) form used to notify the market of new share issues and related details. It includes specifics about the number of shares issued, the issue price, shareholder approvals, and compliance with the Corporations Act 2001. The document is not a full financial report, earnings release, or management discussion, but rather a formal notification of a capital raising event and share issuance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive capital raising disclosure.
2018-05-15 English
Admedus secures further funding with Placement and SPP 3 pages 92.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Admedus Limited dated 10 May 2018. It details the company's securing of funding through a placement of shares and a share purchase plan (SPP). The content focuses on capital raising activities, including the number of shares issued, the issue price, the amount raised, and the intended use of funds for strategic projects and product commercialization. There is no financial statement or detailed financial performance data included, nor is it a report or presentation. The document is clearly an update on financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 6,000 characters, so it is not a brief announcement of a report publication or a regulatory filing. Confidence is high given the clear focus on capital raising and funding.
2018-05-09 English
Cleansing Statement - SPP 1 page 123.9KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under ASIC Class Order 09/425 related to a share purchase plan. It discusses compliance with regulatory provisions and the intention to issue shares under a share purchase plan without disclosure under the Corporations Act. The document is short (1282 characters) and serves as a regulatory announcement rather than a detailed financial report or capital raising document. It does not contain financial statements or detailed financing updates but is a formal regulatory notice about a share issue plan. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2018-05-09 English
Share Purchase Plan 9 pages 924.8KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement from Admedus Limited regarding a Share Purchase Plan (SPP). It includes detailed terms and conditions of the SPP, instructions for shareholders on how to participate, eligibility criteria, risks, and other relevant information about the capital raising. The document is not a financial report, earnings release, or management discussion but rather an update on a capital raising activity involving issuing new shares to existing shareholders. This fits the definition of a Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing event, not just a brief announcement or a notice of a report publication.
2018-05-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.